|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Commodore Capital LP
✚
|
|
|---|---|
| CRD # | 304370 |
| SEC # | 801-117168 |
| CIK # | 0001831942 |
| AUM | $1.8 B (2025-03-27) |
| Employees | 12 (50% Investors, 0% Brokers) |
| Phone | 212-256-8600 |
| Address | 444 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Merus NV | 185.4 | ||
| Nuvalent Inc | 104.9 | ||
| Xenon Pharmaceuticals Inc | 94.7 | ||
| Imara Inc | 94.1 | ||
| Agios Pharmaceuticals Inc | 77.3 | ||
| Celldex Therapeutics Inc | 70.2 | ||
| Alkermes PLC | 70.1 | ||
| Signal Genetics Inc | 68.2 | ||
| Protagonist Therapeutics Inc | 59.4 | ||
| Cidara Therapeutics Inc | 57.2 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| HF | Commodore Capital Master LP | [2019-07-15] | 482.8 | 1,763.8 |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 1,763.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 1,763.8 |
| By Discretionary | ||
| Discretionary | 3 | 1,763.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 1,763.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 506.2 | |
| United States Persons | 1,257.6 | |
| Total | 3 | 1,763.8 |
| Form D Directors | # Filings | # Firms | 2011 - 2025 |
|---|---|---|---|
| Jennifer Collins | 227 | ||
| Mark Cook | 124 | ||
| Tammy Jennissen | 131 | ||
| Trinda Blackmore | 42 | ||
| Egen Atkinson | 2 | ||
| Michael Kramarz | 2 | ||
| Commodore Capital LP | 2 | ||
| Ameya Bapat | 1 | ||
| Anand Pandya | 1 |
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001831942] | |
| 3 | [0001831942] | |
| 4 | [0001831942] | |
| SC 13G | [0001831942] |
| Form 3/4/5 Subject | 2011 - 2025 |
|---|---|
| Vera Therapeutics, Inc. | |
| Commodore Capital LP | |
| Vistagen Therapeutics, Inc. | |
| Ambrx Biopharma Inc. | |
| Enliven Therapeutics, Inc. | |
| Satsuma Pharmaceuticals, Inc. |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Absolute Investment Advisers LLC
✚
|
FL | 1.8 |
|
Sagefield Investment Group LP
✚
|
TX | 1.8 |
|
APS Asset Management PTE Ltd
✚
|
1.8 | |
|
Lancaster Investment Management LLP
✚
|
1.8 | |
|
Styrax Capital LP
✚
|
NY | 1.8 |
|
Boundary Creek Advisors LP
✚
|
NY | 1.8 |
|
Parsifal Capital Management LP
✚
|
CT | 1.8 |
|
Analog Century Management LP
✚
|
NY | 1.7 |
|
Oribel Capital Management LP
✚
|
NY | 1.7 |
|
Eversept Partners LP
✚
|
NY | 1.7 |